-
公开(公告)号：US11932689B2
公开(公告)日：2024-03-19
申请号：US17125135
申请日：2020-12-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Felix Unverdorben , Sebastian Bunk , Martin Hofmann , Dominik Maurer , Meike Hutt , Claudia Wagner , Leonie Alten
IPC: C07K14/725 , A61P35/00 , C07K14/775 , C07K14/78 , C07K16/18 , C07K16/28 , C12N5/0783 , C12N15/62
CPC classification number: C07K16/28 , A61P35/00 , C07K14/7051 , C07K14/775 , C07K14/78 , C07K16/18 , C07K16/2809 , C12N5/0636 , C12N15/62 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03 , C07K2319/33 , C12N2510/00
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US11905328B2
公开(公告)日：2024-02-20
申请号：US16035403
申请日：2018-07-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin Hofmann , Felix Unverdorben , Sebastian Bunk , Dominik Maurer
CPC classification number: C07K16/2809 , C07K16/1045 , C07K16/2833 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/626 , C07K2317/94
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US11859009B2
公开(公告)日：2024-01-02
申请号：US17934303
申请日：2022-09-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Gabriele Pszolla , Martin Hofmann , Meike Hutt , Sebastian Bunk , Felix Unverdorben , Frank Schwoebel , Dominik Maurer , Maike Jaworski , Claudia Wagner , Florian Schwoerer , Heiko Schuster
CPC classification number: C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
Patent Agency Ranking
公开(公告)号：US12162940B2
公开(公告)日：2024-12-10
申请号：US17736699
申请日：2022-05-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Sebastian Bunk , Felix Unverdorben , Martin Hofmann
IPC: C07K16/28 , C07K14/725 , C07K16/30 , C12N5/0783
Abstract: Antigen binding polypeptide specifically binding to α/β T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector, and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the α/β TCR/CD3 complex.
-
公开(公告)号：US20190016803A1
公开(公告)日：2019-01-17
申请号：US16035420
申请日：2018-07-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin Hofmann , Felix Unverdorben , Sebastian Bunk , Dominik Maurer
IPC: C07K16/28
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US12269881B2
公开(公告)日：2025-04-08
申请号：US18538242
申请日：2023-12-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike Hutt , Felix Unverdorben , Sebastian Bunk , Dominik Maurer , Martin Hofmann , Gabriele Pszolla , Sara Yousef , Claudia Wagner , Frank Schwoebel , Heiko Schuster
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US11840577B2
公开(公告)日：2023-12-12
申请号：US16943779
申请日：2020-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike Hutt , Felix Unverdorben , Sebastian Bunk , Dominik Maurer , Martin Hofmann , Gabriele Pszolla , Sara Yousef , Claudia Wagner , Frank Schwoebel , Heiko Schuster
IPC: C07K16/30 , C07K16/46 , C07K14/725 , A61P35/00
CPC classification number: C07K16/30 , A61P35/00 , C07K14/7051 , C07K2317/24 , C07K2317/32 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US10889645B2
公开(公告)日：2021-01-12
申请号：US16736337
申请日：2020-01-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Felix Unverdorben , Sebastian Bunk , Martin Hofmann , Dominik Maurer , Meike Hutt , Claudia Wagner , Leonie Alten
IPC: C07K14/725 , C07K16/28 , C07K16/18 , C07K14/78 , A61P35/00 , C07K14/775 , C12N5/0783 , C12N15/62
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.015 seconds)
